Other

University of California

Millennium Pharmaceuticals Limited

Millenium Pharmaceuticals, Inc.

The University of Costa Rica

Nelson B Freimer

Hong M Chen

Pedro E Leon

Lodewijk Sandkuijl

Lynne Allison McInnes

Victor I Reus

Michael Escamilla

Susan K Service

The present invention is directed to methods of detecting the presence of a bipolar mood disorder susceptibility locus in an individual, comprising analyzing a sample of DNA for the presence of a DNA polymorphism on the short arm of chromosome 18 between the telomere and D18S481, wherein the DNA polymorphism is associated with a form of bipolar mood disorder. The invention for the first time provides strong evidence of a susceptibility gene for bipolar mood disorder that is located in the terminal 5 cM region of the short arm of chromosome 18. The disclosure describes the use of linkage analysis and genetic markers in this 5 cM region to fine map the region and the use of genetic markers to genetically diagnose (genotype) bipolar mood disorder in individuals, to confirm phenotypic diagnoses of bipolar mood disorder, to determine appropriate treatments for patients with particular genotypic subtypes. Isolated polynucleotides useful for genetic linkage analysis of BP-I and methods for obtaining such isolated polynucleotides are also described.

Methods for treating bipolar mood disorder associated with markers on chromosome 18p

The present invention relates of the mammalian HKNG1 gene, a gene associated with bipolar affective disorder (BAD) in humans. The invention relates, in particular, to methods for the diagnostic evaluation, genetic testing and prognosis of HKNG1 neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder.

Methods and compositions for diagnosing and treating chromosome -18p related disorders

Methods and compositions for diagnosing and treating chromosome-18p related disorders

The present invention relates to the mammalian rTS gene, a gene associated with bipolar affective disorder (BAD) in humans. The invention relates to methods for the identification of compounds that modulate the expression of rTS and to using such compounds as therapeutic agents in the treatment of rTS disorders and neuropsychiatric disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of rTS neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder, and to methods and compositions for the treatment these disorders.

Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders

The present invention relates to the mammalian Hcen-2 gene. The invention relates to methods for the identification of compounds that modulate the expression of Hcen-2 and to using such compounds as therapeutic agents in the treatment of Hcen-2 disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of Hcen-2 mediated disorders, and to methods and compositions for the treatment these disorders. The invention also relates to use of the Hcen-2 gene and/or gene products as markers for fine structure mapping of a region of human chromosome 18, including a region of the chromosome involved in mediating neuropsychiatric disorders.

The present invention is directed to methods of detecting the presence of a bipolar mood disorder susceptibility locus in an individual, comprising analyzing a sample of DNA for the presence of a DNA polymorphism on the long arm of chromosome 18 between markers D18S469 and D18S554, wherein the DNA polymorphism is associated with a form of bipolar mood disorder. The invention for the first time provides strong evidence of a susceptibility gene for bipolar mood disorder that is located in the 18q22-q23 region of the long arm of chromosome 18. The disclosure describes the use of linkage analysis and genetic markers in this 18q22-q23 region to fine map the region and the use of genetic markers to genetically diagnose (genotype) bipolar mood disorder in individuals, to confirm phenotypic diagnoses of bipolar mood disorder, to determine appropriate treatments for patients with particular genotypic subtypes. Isolated polynucleotides useful for genetic linkage analysis of BP-I and methods for obtaining such isolated polynucleotides are also described.

Methods for treating bipolar mood disorder associated with markers on

The present invention relates to the mammalian fsh05 gene, a novel gene associated with bipolar affective disorder (BAD) in humans. The invention encompasses fsh05 nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, fsh05 gene products and antibodies directed against such gene products, cloning vectors containing mammalian fsh05 gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of fsh05 and to using such compounds as therapeutic agents in the treatment of fsh05 disorders and neuropsychiatric disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of fsh05 disorders and neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder, and to methods and compositions for the treatment these disorders.

Chromosome 18 marker

The present invention relates to the mammalian fsh22 gene, a novel gene associated with bipolar affective disorder (BAD) in humans. The invention encompasses fsh22 nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, fsh22 gene products and antibodies directed against such gene products, cloning vectors containing mammalian fsh22 gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of fsh22 and to using such compounds as therapeutic agents in the treatment of fsh22 disorders and neuropsychiatric disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of fsh22 disorders and neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder, and to methods and compositions for the treatment these disorders.

The present invention relates to the mammalian fsh16 gene, a novel gene associated with bipolar affective disorder (BAD) in humans. The invention encompasses fsh16 nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, fsh16 gene products and antibodies directed against such gene products, cloning vectors containing mammalian fsh16 gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of fsh16 and to using such compounds as therapeutic agents in the treatment of fsh16 disorders and neuropsychiatric disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of fsh16 disorders and neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder, and to methods and compositions for the treatment these disorders.

Methods and compositions for the diagnosis and treatment of

The present invention relates to the mammalian fsh15w6 gene, a novel gene associated with bipolar affective disorder (BAD) in humans. The invention encompasses fsh15w6 nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, fsh15w6 gene products and antibodies directed against such gene products, cloning vectors containing mammalian fsh15w6 gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of fsh15w6 and to using such compounds as therapeutic agents in the treatment of fsh15w6 disorders and neuropsychiatric disorders. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of fsh15w6 disorders and neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder, and to methods and compositions for the treatment these disorders.

Growing community of inventors

San Francisco, CA, United States of America

Nelson B Freimer